CACI Awarded Task Order to Support Defense Intelligence Agency (DIA) National Center for Medical Intelligence

CACI International Inc (NYSE: CACI) announced today that it won a single-award, five-year task order to provide expertise to the Defense Intelligence Agency (DIA) National Center for Medical Intelligence (NCMI). This new contract with the Defense Medical Intelligence and Global Health Security (DMIGHS) includes enhanced activities assisting NCMI in effectively providing medical intelligence support on foreign health threats and other medical issues to protect U.S. interests worldwide. This work is part of the Solutions for Intelligence Analysis 3 (SIA 3) indefinite delivery, indefinite quantity (IDIQ) contract vehicle.

“CACI is proud to take on this new challenge with our longstanding customer, DIA, to provide expert intelligence and analysis support to assist intelligence gathering for the National Center for Medical Intelligence,” said John Mengucci, CACI President and Chief Executive Officer. “CACI’s experts are uniquely qualified to help DIA achieve information advantage by strengthening the agency’s ability to confidently and accurately transform data into actionable insights and meet critical intelligence analysis objectives.”

NCMI protects the nation by providing evaluation and all-source analysis of worldwide health threats and issues, including foreign medical capabilities, infectious disease, environmental health risks, developments in biotechnology and biomedical subjects of national and military importance, and support to force protection. CACI performs intelligence analysis focused on medical protection, identification, and analysis of foreign health threats to better protect U.S. interests both domestically and internationally.

About CACI

At CACI International Inc (NYSE: CACI), our 23,000 talented and dynamic employees are ever vigilant in delivering distinctive expertise and differentiated technology to meet our customers’ greatest challenges in national security and government modernization. We are a company of good character, relentless innovation, and long-standing excellence. Our culture drives our success and earns us recognition as a Fortune World's Most Admired Company. CACI is a member of the Fortune 1000 Largest Companies, the Russell 1000 Index, and the S&P MidCap 400 Index. For more information, visit us at www.caci.com.

There are statements made herein which do not address historical facts, and therefore could be interpreted to be forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors that could cause actual results to differ materially from anticipated results. The factors that could cause actual results to differ materially from those anticipated include, but are not limited to, the risk factors set forth in CACI’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, and other such filings that CACI makes with the Securities and Exchange Commission from time to time. Any forward-looking statements should not be unduly relied upon and only speak as of the date hereof.

CACI-Category-Business Wire

View source version on businesswire.com: https://www.businesswire.com/news/home/20231219993373/en/